Perrigo

This article was originally published in The Tan Sheet

16 Jul 2001

Executive Summary

Private labeler receives FDA clearance for acetaminophen, aspirin and caffeine tablets (ANDA 75-794) July 12. Product is first approved generic version of Bristol-Myers Squibb's Excedrin Migraine, which lost marketing exclusivity Jan. 14. Perrigo says it will not launch store brand equivalent until Spring 2002, however, as it focuses on shipping products planned before quality control problems hampered launches last year (1see item, p. 5)

Existing Subscriber? Sign in to continue reading.

New to Pink Sheet? Start a free trial today!

Table
View full table

Topics

Industries
Consumer
Subjects
OTC Drugs

ASK THE ANALYST
Email

Print
Bookmark
Share

Tags:

Consumer OTC Drugs

You must sign in to use this functionality

Authentication.SignIn.HeadSignInHeader

PS092799

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

PS092799

All set! This article has been sent to my@email.address.

All fields are required. For multiple recipients, separate email addresses with a semicolon.

Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.

Perrigo

Executive Summary

Topics

You must sign in to use this functionality

Authentication.SignIn.HeadSignInHeader

Register

Ask The Analyst

Email Article

Perrigo

Executive Summary

Related Content

Perrigo

Topics

You must sign in to use this functionality

Authentication.SignIn.HeadSignInHeader

Register

Ask The Analyst

Email Article

Sign In To Set a Search Alert